Cargando…

Beta Blockers and Melanoma

Understanding the mechanisms of cancer immune-tolerance is one of the most important challenges. Several studies have demonstrated the potential anticarcinogenic effects of beta-blockers, in patients with prostate cancer, breast cancer, and melanoma. At the other side variety of dermatoses may be ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Vojvodic, Aleksandra, Vojvodic, Petar, Vlaskovic-Jovicevic, Tatjana, Sijan, Goran, Dimitrijevic, Sanja, Peric-Hajzler, Zorica, Matovic, Dusica, Wollina, Uwe, Tirant, Michael, Thuong, Nguyen Van, Fioranelli, Massimo, Lotti, Torello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Republic of Macedonia 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6910815/
https://www.ncbi.nlm.nih.gov/pubmed/31850134
http://dx.doi.org/10.3889/oamjms.2019.782
_version_ 1783479164397944832
author Vojvodic, Aleksandra
Vojvodic, Petar
Vlaskovic-Jovicevic, Tatjana
Sijan, Goran
Dimitrijevic, Sanja
Peric-Hajzler, Zorica
Matovic, Dusica
Wollina, Uwe
Tirant, Michael
Thuong, Nguyen Van
Fioranelli, Massimo
Lotti, Torello
author_facet Vojvodic, Aleksandra
Vojvodic, Petar
Vlaskovic-Jovicevic, Tatjana
Sijan, Goran
Dimitrijevic, Sanja
Peric-Hajzler, Zorica
Matovic, Dusica
Wollina, Uwe
Tirant, Michael
Thuong, Nguyen Van
Fioranelli, Massimo
Lotti, Torello
author_sort Vojvodic, Aleksandra
collection PubMed
description Understanding the mechanisms of cancer immune-tolerance is one of the most important challenges. Several studies have demonstrated the potential anticarcinogenic effects of beta-blockers, in patients with prostate cancer, breast cancer, and melanoma. At the other side variety of dermatoses may be caused or aggravated by β-blockers-psoriasis, lichen planus-like drug eruptions (LDE), acrocyanosis, alopecia etc. Beta-blockers have been shown to improve the prognosis of melanoma patients significantly. Propranolol inhibits melanoma by downregulating the tumour angiogenesis but also tumour cell proliferation, invasiveness and local immune suppression. Studies showed that only β3-but, not β2-adrenoceptors, were up-regulated under hypoxia in peripheral blood mononuclear cells and selectively expressed in immune cell sub-populations including Treg, MDSC, and NK. They increased NK and CD8 number and cytotoxicity. Catecholamines may retard melanoma progression and that β-blockers may have unrecognised potential as a therapeutic intervention for melanoma, in the prevention of the growth of melanoma in all stages and as adjuvant therapy with other targeted and immune therapies for melanoma.
format Online
Article
Text
id pubmed-6910815
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Republic of Macedonia
record_format MEDLINE/PubMed
spelling pubmed-69108152019-12-17 Beta Blockers and Melanoma Vojvodic, Aleksandra Vojvodic, Petar Vlaskovic-Jovicevic, Tatjana Sijan, Goran Dimitrijevic, Sanja Peric-Hajzler, Zorica Matovic, Dusica Wollina, Uwe Tirant, Michael Thuong, Nguyen Van Fioranelli, Massimo Lotti, Torello Open Access Maced J Med Sci Review Article Understanding the mechanisms of cancer immune-tolerance is one of the most important challenges. Several studies have demonstrated the potential anticarcinogenic effects of beta-blockers, in patients with prostate cancer, breast cancer, and melanoma. At the other side variety of dermatoses may be caused or aggravated by β-blockers-psoriasis, lichen planus-like drug eruptions (LDE), acrocyanosis, alopecia etc. Beta-blockers have been shown to improve the prognosis of melanoma patients significantly. Propranolol inhibits melanoma by downregulating the tumour angiogenesis but also tumour cell proliferation, invasiveness and local immune suppression. Studies showed that only β3-but, not β2-adrenoceptors, were up-regulated under hypoxia in peripheral blood mononuclear cells and selectively expressed in immune cell sub-populations including Treg, MDSC, and NK. They increased NK and CD8 number and cytotoxicity. Catecholamines may retard melanoma progression and that β-blockers may have unrecognised potential as a therapeutic intervention for melanoma, in the prevention of the growth of melanoma in all stages and as adjuvant therapy with other targeted and immune therapies for melanoma. Republic of Macedonia 2019-08-30 /pmc/articles/PMC6910815/ /pubmed/31850134 http://dx.doi.org/10.3889/oamjms.2019.782 Text en Copyright: © 2019 Aleksandra Vojvodic, Petar Vojvodic, Tatjana Vlaskovic-Jovicevic, Goran Sijan, Sanja Dimitrijevic, Zorica Peric-Hajzler, Dusica Matovic, Uwe Wollina, Michael Tirant, Nguyen Van Thuong, Massimo Fioranelli, Torello Lotti. http://creativecommons.org/licenses/CC BY-NC/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)
spellingShingle Review Article
Vojvodic, Aleksandra
Vojvodic, Petar
Vlaskovic-Jovicevic, Tatjana
Sijan, Goran
Dimitrijevic, Sanja
Peric-Hajzler, Zorica
Matovic, Dusica
Wollina, Uwe
Tirant, Michael
Thuong, Nguyen Van
Fioranelli, Massimo
Lotti, Torello
Beta Blockers and Melanoma
title Beta Blockers and Melanoma
title_full Beta Blockers and Melanoma
title_fullStr Beta Blockers and Melanoma
title_full_unstemmed Beta Blockers and Melanoma
title_short Beta Blockers and Melanoma
title_sort beta blockers and melanoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6910815/
https://www.ncbi.nlm.nih.gov/pubmed/31850134
http://dx.doi.org/10.3889/oamjms.2019.782
work_keys_str_mv AT vojvodicaleksandra betablockersandmelanoma
AT vojvodicpetar betablockersandmelanoma
AT vlaskovicjovicevictatjana betablockersandmelanoma
AT sijangoran betablockersandmelanoma
AT dimitrijevicsanja betablockersandmelanoma
AT perichajzlerzorica betablockersandmelanoma
AT matovicdusica betablockersandmelanoma
AT wollinauwe betablockersandmelanoma
AT tirantmichael betablockersandmelanoma
AT thuongnguyenvan betablockersandmelanoma
AT fioranellimassimo betablockersandmelanoma
AT lottitorello betablockersandmelanoma